Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc Malaria Vaccine Disappoints In Trial In African Babies-Reuters


Friday, 9 Nov 2012 06:27am EST 

Reuters reported that Glaxosmithkline Plc experimental malaria vaccine touted as a new weapon in the fight to eradicate the disease proved only 30% effective when given to babies as part Africa's ever clinical trial. The surprisingly poor result for the potential vaccine against malaria leaves uncertain whether it can have a useful role in fighting the mosquito-borne disease that kills hundreds of thousands of children a year. Results from the final-stage trial with 6,537 babies aged six to 12 weeks showed the vaccine provided "modest protection", reducing episodes of the disease by 30% compared to immunisation with a control vaccine, researchers said on November 09, 2012. Details of the malaria trial, which is Africa's ever clinical trial involving almost 15,500 children in seven countries, were presented at a medical meeting in Cape Town and published online by the New England Journal of Medicine. 

Company Quote

50.06
-3.16 -5.94%
23 Jul 2014